Want to see MLSS full AI Analyst Report?
MLSS Stock Chart & Stats
$0.54
$0.01(3.13%)
At close: 4:00 PM EDT
$0.54
$0.01(3.13%)
Day’s Range― - ―
52-Week Range$0.22 - $0.64
Previous Close$0.4
Volume145.61K
Average Volume (3M)167.62K
Market Cap
$41.17M
Enterprise Value$28.44
Total Cash (Recent Filing)$2.07M
Total Debt (Recent Filing)$615.70K
Price to Earnings (P/E)―
Beta0.81
Next Earnings
Nov 12, 2026EPS Estimate
-0.01Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.05
Shares Outstanding88,739,180
10 Day Avg. Volume88,806
30 Day Avg. Volume167,621
Financial Highlights & Ratios
PEG Ratio-0.21
Price to Book (P/B)7.97
Price to Sales (P/S)2.50
P/FCF Ratio-7.64
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$1.50Price Target Upside177.78% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-0.04
Revenue Forecast (FY)$9.97M
Bulls Say, Bears Say
Bulls Say
Revenue Growth And Reimbursement ExpansionGrowing revenue and established Medicare reimbursement create a stronger commercial foundation for CompuFlo. Broader payer coverage can reduce adoption barriers, support direct sales expansion, and improve the durability of future medical-segment growth.
Clinical Validation And Distribution AccessThird-party clinical evidence strengthens the product’s value proposition, while federal distribution access expands its reachable market. Together, these advantages can support physician adoption and create durable channels beyond the company’s existing customer base.
Strong Gross Margins And Expense DisciplineHigh gross margins indicate attractive product economics, while lower operating expenses show improving cost control. If revenue scales through reimbursement and distribution channels, this operating discipline could provide meaningful leverage toward eventual breakeven.
Bears Say
Persistent Losses And Negative Cash GenerationThe company remains far from sustained profitability and is not yet self-funding. Continued losses and negative free cash flow may constrain investment in sales capacity, reimbursement support, and product development, increasing reliance on external financing.
Eroded Equity Base And Capital DependenceAlthough leverage is modest, the shrinking equity base reduces financial resilience and limits flexibility if cash burn persists. The company may need additional capital before reaching breakeven, creating dilution or funding risk over the medium term.
Scaling And Cost-Pressure Execution RisksCommercial traction has not yet translated into a large, diversified revenue base. Limited staffing may slow lead conversion and reimbursement execution, while import-related costs can erode margins as the company scales, challenging the path to profitability.
Milestone Scientific News
MLSS FAQ
What was Milestone Scientific’s price range in the past 12 months?
Milestone Scientific lowest stock price was $0.22 and its highest was $0.64 in the past 12 months.
What is Milestone Scientific’s market cap?
Milestone Scientific’s market cap is $41.17M.
When is Milestone Scientific’s upcoming earnings report date?
Milestone Scientific’s upcoming earnings report date is Nov 12, 2026 which is in 68 days.
How were Milestone Scientific’s earnings last quarter?
Milestone Scientific released its earnings results on Aug 14, 2026. The company reported -$0.01 earnings per share for the quarter.
Is Milestone Scientific overvalued?
According to Wall Street analysts Milestone Scientific’s price is currently Undervalued.
Does Milestone Scientific pay dividends?
Milestone Scientific does not currently pay dividends.
What is Milestone Scientific’s EPS estimate?
Milestone Scientific’s EPS estimate is -0.01.
How many shares outstanding does Milestone Scientific have?
Milestone Scientific has 88,739,180 shares outstanding.
What happened to Milestone Scientific’s price movement after its last earnings report?
Milestone Scientific reported an EPS of -$0.01 in its last earnings report. Following the earnings report the stock price went down -10.488%.
Which hedge fund is a major shareholder of Milestone Scientific?
Currently, no hedge funds are holding shares in MLSS
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Milestone Scientific Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$1.50 (177.78% Upside)
$1.50 (177.78% Upside)
Blogger Sentiment
Bullish
MLSS Sentiment 100%
Sector Average 60%
Sector Average 60%
Technicals
SMA
Positive
20 days / 200 days
Momentum
-26.87%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
3.69%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Milestone Scientific
Milestone Scientific Inc. is dedicated to the innovation, refinement, and global distribution of advanced diagnostic and therapeutic injection technologies and devices. These solutions cater to the medical, dental, and cosmetic industries, with a presence in the United States, China, and other international markets. The company's operations are divided into two main segments: Dental and Medical. Within its Dental division, key products include CompuDent and the STA Single Tooth Anesthesia System, both instrumental for delivering local anesthetics across all dental procedures. For broader applications, the firm offers CompuFlo, a sophisticated computer-controlled system capable of delivering drugs, anesthetics, and other medicaments comfortably and precisely, as well as aspirating bodily fluids or prior injections. Complementing this, a disposable injection handpiece provides precise tactile control during administration. In the Medical segment, Milestone Scientific introduces the CompuFlo Epidural, a computer-guided anesthesia system designed for a variety of medical applications. Additionally, their CompuMed system is utilized in numerous specialized procedures, including plastic surgery, hair restoration, colorectal surgery, podiatry, dermatology, and orthopedics, among others. Headquartered in Livingston, New Jersey, Milestone Scientific Inc. was established in 1989.
MLSS Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call presented multiple clear operational and commercial wins — robust revenue growth, a large percentage increase in medical segment revenue, important Medicare reimbursement milestones, strong third-party clinical validation (91% reduction in complication odds), new federal distribution access, and improved expense discipline that reduced net loss. Offsetting these positives are margin pressure from increased product/import costs, a non-recurring ~ $500K international order that tempers near-term sequential revenue (Q3 guide below Q2), medical revenue still coming from a small base, staffing capacity constraints for lead and reimbursement follow-up, and a modest cash balance that could require monitoring. On balance the call emphasized measurable commercial progress and validation and management provided a path to scale reimbursement and federal channels, while acknowledging operational headwinds to be managed.View all MLSS earnings summariesMLSS Stock 12 Month Forecast
Average Price Target
$1.50
▲(177.78% Upside)
Technical Analysis
Retractable Technologies
―
Precision Optics Corporation
―
Nephros
―
Femasys
―
NexGel Inc
―
Ownership Overview
10.03% Insiders
2.92% Mutual Funds
1.21% Other Institutional Investors
83.38% Public Companies and
Individual Investors